Chiesi to buy KalVista for $1.9bn: Q3 2026 close

Deal announcement and why it matters

Chiesi Group and KalVista Pharmaceuticals said they have entered into a definitive agreement under which Chiesi will acquire KalVista in an all-cash transaction. The companies announced the deal on 29 April 2026 from Parma, Italy and Framingham, Massachusetts. Chiesi said the acquisition strengthens its long-term rare diseases strategy and expands its commercial footprint in the United States. For KalVista, the agreement sets a defined cash exit at a fixed price, subject to the transaction completing. The deal also gives Chiesi control of EKTERLY (sebetralstat), described as an oral, on-demand treatment for hereditary angioedema (HAE). Chiesi said the addition strengthens its rare immunology portfolio and addresses unmet needs for patients who require accessible therapies. Both companies said their boards unanimously approved the transaction.

Purchase price, structure, and headline value

Under the terms of the agreement, Chiesi will commence a tender offer to acquire all outstanding shares of KalVista for $17.00 per share in cash. The total equity value implied at closing is approximately $1.9 billion. Chiesi said the transaction is not subject to any financing condition. The offer price represents a 36% premium to KalVista’s 30-day volume-weighted average share price as of 28 April 2026, according to the merger agreement terms described by the companies. Reuters separately reported the offer represented a premium of about 40% to KalVista’s last closing price. If the tender offer is successfully completed, Chiesi will acquire any remaining shares not tendered through a second-step merger for the same $17.00 per share consideration. The companies said the deal is expected to close in the third quarter of 2026.

How the tender offer is expected to work

Chiesi said a wholly owned subsidiary will commence the tender offer for all outstanding shares of KalVista’s common stock. Closing is subject to customary conditions, including the tender of at least a majority of the then outstanding KalVista shares. The companies also flagged the need for regulatory approvals and other customary offer conditions. The structure is designed to allow Chiesi to move from a tender offer to a back-end merger if the required thresholds are met. The deal terms indicate a single cash price applies across both steps, which reduces uncertainty around the eventual per-share outcome if the deal proceeds. The companies did not disclose a specific date for when the tender offer would begin, beyond stating Chiesi will commence it.

EKTERLY (sebetralstat) and the rare immunology focus

A central rationale for the acquisition is EKTERLY (sebetralstat), which Chiesi will take responsibility for after completion. Chiesi described EKTERLY as a differentiated oral, on-demand treatment for hereditary angioedema. The company said the therapy addresses a significant unmet need for patients seeking effective and accessible options. Another source in the provided material described EKTERLY as FDA-approved and said it generated $19 million in sales last year. Chiesi said its rare disease initiatives are spearheaded by Chiesi Global Rare Diseases, a business unit focused on research, development, and commercialization for rare and ultra-rare conditions. The acquisition is positioned as a portfolio expansion in rare immunology, rather than a broad-based diversification.

Strategic context: scale and revenue targets

Reuters reported the transaction is the largest acquisition in the family-owned group’s history. Chiesi also characterised the deal as its most substantial acquisition to date in value terms and an important milestone in its rare diseases strategy. Reuters reported Chiesi linked the addition of EKTERLY to its longer-term financial ambition. Specifically, the report said EKTERLY would help Chiesi meet a 2030 revenue target of 6 billion euros, up from 3.6 billion euros in 2025. These figures were provided as targets and historical levels in the source material, not as guidance updates tied to the closing of this deal. The company’s stated aim is to build out a durable rare disease franchise through science and commercialization capabilities.

Market reaction: KalVista shares jump

The announcement triggered a sharp move in KalVista’s stock price. Reuters reported shares jumped 38.9% after the deal announcement. Another item in the provided material described a surge of approximately 39% in premarket trading on 29 April 2026. MarketBeat reported the stock had previously closed at $19.24 and that the news pushed the shares to a 52-week high with heavy volume. A separate market data snippet showed a real-time estimate around $16.68 to $16.72 on 29 April 2026, reflecting a roughly 38.7% to 38.9% gain on the day in that snapshot. The move is consistent with investors pricing in the $17.00 cash offer, while still reflecting typical deal-completion risk and timing value.

Key numbers at a glance

Conditions, approvals, and timing

The companies said the deal is expected to close in Q3 2026, but only after customary closing conditions are satisfied. The key shareholder condition is the tender of at least a majority of KalVista shares. Regulatory approvals are also required, alongside other customary offer conditions. The companies did not list specific jurisdictions or agencies in the text provided. The absence of a financing condition reduces one common execution risk, but the timeline still depends on the tender process and the regulatory pathway. Until closing, KalVista remains a Nasdaq-listed company, and the market price may continue to reflect probability-weighted expectations for completion.

Advisers and reported financial signals

Reuters reported Lazard is advising Chiesi on the deal and Centerview Partners is acting as financial adviser to KalVista. The provided material also included third-party metrics that framed KalVista’s pre-deal profile: an indicated market capitalisation of approximately $185.52 million, a GF Score of 24/100, and insider selling of $1.6 million over the past three months. These metrics were presented as context by a separate source and were not part of the companies’ joint announcement. Separately, MarketBeat noted that Stifel Nicolaus had raised its target price to $12.00 on 26 March 2026, prior to the acquisition news.

Revenue and sales figures mentioned (normalised units)

All revenue and sales figures below are presented in a single unit base of million (as reported, without currency conversion).

What this means for the rare disease landscape

Chiesi is using the KalVista acquisition to add a specific rare immunology therapy to its portfolio and to deepen its presence in the United States. The asset focus on an oral, on-demand HAE treatment is notable because it targets an established rare disease category where patient access and convenience can materially influence uptake. For investors, the main near-term variables are deal completion and timing, given the fixed $17.00 per share cash consideration. For the sector, the transaction underscores continued appetite for rare disease assets where commercial execution can be scaled by a larger platform. The next major milestone is the tender offer process and progress toward the stated Q3 2026 closing window.

Conclusion

Chiesi’s agreement to acquire KalVista for $17.00 per share values the U.S.-listed company at about $1.9 billion and is expected to close in Q3 2026, subject to shareholder tender and regulatory conditions. If completed, Chiesi will take over EKTERLY (sebetralstat) and expand its rare immunology footprint. The immediate market response was a roughly 38% to 39% jump in KalVista shares as investors priced in the cash offer. The next updates are likely to come through the tender offer launch, any regulatory clearance milestones, and closing-condition progress disclosures.